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                                  The epidermal growth factor receptor (EGFR), a member of the 
human epidermal growth factor receptor (HER)  –  erbB family of 
receptor tyrosine kinases, represents an important target for cancer 
treatment because its activation stimulates key processes involved in 
tumor growth and progression, including proliferation, angiogene-
sis, invasion, and metastasis. The binding of EGF or other ligands to 
EGFR initiates a mitogenic signaling cascade via several pathways, 
including the RAS  –  RAF  –  mitogen-activated protein kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K)  –  Akt, and phospholipase C     
pathways (  1  ,  2  ). Overexpression of EGFR is found in a range of solid 
tumor types and has been linked to poorer outcomes (  3  ,  4  ). 
  EGFR inhibitors  —  monoclonal antibodies targeting the extracel-
lular domain and small-molecule tyrosine kinase inhibitors  —  have 
expanded the range of treatment options for various solid tumors. 
EGFR-targeted monoclonal antibodies have been extensively stud-
ied in metastatic colorectal cancer (  Table 1  ), whereas tyrosine kinase 
inhibitors have thus far shown little activity in this setting (  5  ,  6  ). 
Cetuximab (ER-K0034, Erbitux, Merck-Serono KgaA, Darmstadt, 
Germany; ImClone       Systems Inc, New York, NY), the ﬁ  rst anti-
EGFR monoclonal antibody to be approved for clinical use for meta-
static colorectal cancer, is a chimeric mouse  –  human monoclonal 
antibody that has been evaluated primarily in combination with che-
motherapy (  7    –    10  ) but also as monotherapy (  7  ,  11  ,  12  ). Panitumumab 
(ABX-EGF, Vectibix; Amgen Inc, Thousand Oaks, CA), a fully 
human monoclonal antibody, has shown efﬁ  cacy as monotherapy in 
chemotherapy-refractory patients with metastatic colorectal cancer 
(  13  ), and ongoing chemotherapy combination trials in earlier lines of 
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treatment have reported acceptable interim safety data (  14  ,  15  ). In 
addition, cetuximab and panitumumab have both been evaluated in 
combination with bevacizumab, a monoclonal antibody targeting the 
vascular endothelial growth factor (VEGF), plus standard ﬁ  rst-line 
chemotherapy (  16  ,  17  ). However, increased toxicity and a shorter 
progression-free interval were observed in the experimental groups 
compared with the control groups. Thus, the strategy of combining 
both an EGFR inhibitor and a VEGF inhibitor with chemotherapy 
appears to be detrimental and is not being pursued further.         
    Affiliations of authors:   The Falck Division of Medical Oncology, Department 
of Oncology, Ospedale Niguarda Ca  ’   Granda, Milan, Italy (SS, AS-B); 
Laboratory of Molecular Genetics, Institute for Cancer Research and 
Treatment, University of Torino Medical School, Turin, Italy (FDN, AB); 
Kilconquhar, Fife      , Scotland (JB);  Fondazione Italiana Ricerca Cancro Institute 
of Molecular Oncology      , Milan, Italy (AB)  .     
    Correspondence to:   Salvatore Siena, MD, The Falck Division of Medical 
Oncology,       Ospedale Niguarda Ca  ’   Granda, Piazza Ospedale Maggiore 3, 20162 
Milan, Italy (e-mail:   salvatore.siena@ospedaleniguarda.it  ); Alberto Bardelli, 
PhD, Laboratory of Molecular Genetics, Institute for Cancer Research and 
Treatment, University of Torino Medical School, Strada Provinciale 142, Km 
3.95, 10060 Candiolo, Turin, Italy   (e-mail: a.bardelli@unito.it)  .   
      See   “Funding” and “Notes” following “References.”   
      DOI:   10.1093/jnci/djp280   
    © The Author 2009. Published by Oxford University Press.   
  This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
    Advance Access publication on September 8, 2009.   jnci.oxfordjournals.org    JNCI | Review 1309
  Cetuximab and panitumumab appear to have similar efﬁ  cacy, 
achieving fairly modest but clinically meaningful objective 
response rates of approximately 10% when used as monotherapy 
for chemotherapy-refractory EGFR-expressing metastatic col-
orectal cancers (  7  ,  11    –    13  ,  18  ). However, panitumumab is likely to 
be less immunogenic than cetuximab because of its fully human 
composition and, indeed, panitumumab seldom gives rise to 
severe infusion reactions (  13  ). Such events may occur in up to 
22% of cetuximab-treated patients, depending on geographical 
region (  19  ,  20  ), and appear to be commonly associated with pre-
existing speciﬁ  c IgE antibodies against the oligosaccharide com-
ponent of the cetuximab molecule, galactose-    -1,3-galactose (  21  ). 
  Positive EGFR protein expression, as determined by immuno-
histochemistry, was initially selected as an entry criterion for studies 
evaluating EGFR inhibitors on the assumption that sensitivity to 
such agents was associated with EGFR expression. However, a large 
body of evidence from patients who were treated with monoclonal 
antibodies for metastatic colorectal cancer ( 7  ,  11  ,  13  ,  22  ,  23  ) or tyrosine 
kinase inhibitors for other solid tumors (  24  ,  25  ) indicates that this 
biomarker is poorly associated with response to EGFR inhibitors in 
the clinical setting. Objective responses have been observed in 
patients with low or negative, as well as high, EGFR protein expres-
sion, as determined by immunohistochemistry. These ﬁ  ndings have 
led to intense research to identify alternative predictive molecular 
biomarkers that can be used to identify patients who are most likely 
to beneﬁ  t from EGFR-targeted treatment. This review discusses 
progress made toward these ends with a focus on treatment of meta-
static colorectal cancer with anti-EGFR monoclonal antibodies. 
  Literature was identiﬁ  ed in PubMed and oncology conference 
databases by use of the search terms “colorectal cancer” and 
“molecular markers” and retrieved articles were evaluated by the 
authors. All fully published clinical data relating to clinical 
response to treatment with monoclonal antibodies in metastatic 
colorectal cancer were considered for inclusion, as well as key 
conference abstracts. Additional searches of the same databases 
were performed to identify suitable background information. 
    Predicting Response: Molecular Biomarkers 
  Early work exploring molecular biomarkers of response to EGFR-
targeted monoclonal antibodies (ie, cetuximab or panitumumab) as 
alternatives to EGFR protein determined by immunohistochemistry 
started in 2005 (  26  ) and was based on retrospective analyses of 
archived tumor tissue from subsets of patients participating in clini-
cal trials. However, more recently studies have been designed to 
incorporate biomarker analysis (eg, the pivotal phase III panitu-
mumab study) (  13  ,  27  ). In general, primary tumor tissue was ana-
lyzed, although metastatic tissue was evaluated in some instances. In 
the majority of studies, cetuximab was given in combination with 
chemotherapy, which could make interpretation difficult, whereas 
to date, panitumumab has been administered almost exclusively as 
monotherapy. Although most biomarker datasets are from chemo-
therapy-refractory or relapsed patients who had received multiple 
previous lines of treatment, first-line data have recently been pre-
sented (  28  ,  29  ). Finally, it should also be mentioned that many analy-
ses were based on objective responses alone, without taking disease 
stabilization into account. 
    Markers Downstream of EGFR 
  A rapidly growing body of knowledge has indicated that growth of 
many tumors is driven by constitutive activation of signaling path-
ways downstream of the EGFR, as will be discussed below.   Figure 1   
shows the interactions between various signaling pathways involved 
in tumor proliferation and progression. Such close interactions 
between these pathways may provide “escape mechanisms” that 
allow tumors to circumvent a pathway that has been pharmacologi-
cally blocked.         
  The interlinked RAS  –  MAPK and PI3K signaling pathways 
(  Figure 1  ) play an important role in tumorigenesis via phosphory-
lation of various proteins and transcription factors that directly 
control cell growth, differentiation, and apoptosis (  1  ,  2  ,  30  ).   KRAS  , 
a member of the rat sarcoma virus (  ras  ) gene family of oncogenes 
(including   KRAS  ,   HRAS  , and   NRAS  ), encodes the guanosine 
diphosphate (GDP)  –   and guanosine triphosphate (GTP)  –  binding 
protein RAS that acts as a self-inactivating intracellular signal 
transducer (  31  ). After binding and activation by GTP, RAS 
recruits the oncogene RAF      , which phosphorylates MAP2K (mito-
gen-activated protein kinase kinase)-1 and MAP2K-2, thus initiat-
ing MAPK signaling that ultimately leads to expression of proteins 
playing important roles in cell growth, differentiation, and sur-
vival. The oncogene   PIK3CA   encodes the p110 subunit of PI3K, 
which can be activated via interaction with RAS proteins (  1  ,  2  ,  30  ). 
  Table 1    .       Anti  –  epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) used for treatment of metastatic colorectal 
cancer (mCRC)   
    Agent Description Company Approved indications Investigational indications   
    Cetuximab (Erbitux) Chimeric mAb Merck-Serono KGaA, 
 Darmstadt,  Germany; 
  ImClone Systems Inc, 
  New York, NY
Treatment of patients with 
 EGFR-expressing,    KRAS   wild-type 
  mCRC in combination with 
  chemotherapy (EU) or irinotecan 
  in irinotecan-refractory disease (US) 
  or as a single agent in patients who 
  have failed oxaliplatin- and irinotecan-
  based therapy or who are intolerant 
  to irinotecan (EU, US)
In combination with other 
 targeted  agents 
  Panitumumab (Vectibix) Fully human mAb Amgen Inc, Thousand 
 Oaks,  CA
Monotherapy for fluoropyrimidine-, 
  oxaliplatin-, and irinotecan-resistant 
  EGFR-expressing mCRC with wild-
 type    KRAS 
In combination with 
 chemotherapy  and/or 
  other targeted agents   1310   Review | JNCI  Vol. 101, Issue 19  |  October 7, 2009
  Mutation in   KRAS  ,   BRAF  , or   PIK3CA   results in continuous acti-
vation of the downstream RAS  –  MAPK or PI3K pathways, regardless 
of whether the EGFR is activated or pharmacologically blocked. 
Such activation in turn enhances transcription of various oncogenes, 
including   MYC  ,   CREB  , and the gene for nuclear factor     B (  1  ,  2  ,  30  ). 
  A recent population-based study of 586 patients with colon 
adenocarcinomas found mutations in  KRAS  ,  BRAF  , and/or  PIK3CA   
in 316 (56%) of the 586 tumors studied (  32  ).   KRAS   is the most 
commonly mutated gene in this pathway, with mutations in 
35%  –  45% of colorectal adenocarcinomas; mutations in   PIK3CA   
(  ≤  20%) and   BRAF   (<15%) are less common (  32    –    37  ). Mutations in 
  PIK3CA   and   KRAS   or   BRAF   may coexist within the same tumor 
(  32  ,  36    –    38  ), but   KRAS   and   BRAF   mutations appear to be mutually 
exclusive (  33  ,  34  ,  39    –    41  ).   KRAS   mutation is thought to be an early 
event in tumorigenesis (  42  ,  43  ), and, in general, metastatic and 
primary sites have been concordant with regard to   KRAS   status 
(  44    –    46  ), with only small differences having been reported (  47  ,  48  ). 
  KRAS   mutations have been explored as prognostic biomarkers 
(independent of anti-EGFR monoclonal antibody treatment), but 
data are conﬂ  icting, reﬂ  ecting differences in datasets and method-
   
    Figure 1    .            Overview of interlinked cellular signaling pathways involved in 
the proliferation and progression of colorectal cancer. Agents targeting 
signaling proteins that have been evaluated or are currently being evalu-
ated in phase II, III, or IV clinical trials for colorectal cancer are shown. The 
epidermal growth factor receptor (EGFR)  –  related family of receptor 
tyrosine kinases includes human epidermal growth factor receptor 
(HER1), EGFR, or c-erbB1; HER2 or c-erbB2; HER3 or c-erbB3; and HER4 
or c-erbB4. C-MET = mesenchymal  –  epithelial transition factor; EGF = 
epidermal growth factor; HDAC = histone deacetylases; HGF = hepatocyte 
growth factor; IGF-1 = insulin-like growth factor-I; IGF-1R = insulin-like 
growth factor-I receptor; IR = insulin receptor; VEGF = vascular endothe-
lial growth factor; VEGF-R = vascular endothelial growth factor receptor.       
ologies and possibly tumor heterogeneity (  32  ,  43  ,  49    –    54  ). 
Retrospective data from 2721 patients with colorectal cancer from 
the RASCAL (ie, the Kirsten ras in Colorectal Cancer Collaborative 
Group) study (  43  ) indicated that   KRAS   mutations may be associ-
ated with increased risk of death (  P   = .002). However, in phase III 
monotherapy studies of cetuximab (  55  ) or panitumumab (  13  ,  27  ), 
  KRAS   mutations did not appear to affect outcome among patients 
receiving only best supportive care. Furthermore,   KRAS   mutations 
do not appear to have a stage-speciﬁ  c prognostic value: No asso-
ciation between tumor   KRAS   mutations and relapse-free survival 
was observed among patients with stage II and stage III colorectal 
cancer in the Pan-European Trials in Adjuvant Colon Cancer 
(PETACC) 3 study (  54  ). 
    KRAS Mutations.             A number of groups undertook retrospective 
testing of   KRAS   status of tumors from patients with metastatic 
colorectal cancer who were treated with cetuximab or panitu-
mumab (with or without chemotherapy) (  26  ,  33  ,  34  ). Lievre et al. 
(  34  ) first reported the link between   KRAS   mutations and lack of 
response to EGFR-targeted monoclonal antibodies, a concept jnci.oxfordjournals.org    JNCI | Review 1311
previously proposed by Moroni et al. (  26  ), based on their cohort 
study (n = 30 patients). These findings were confirmed and 
extended to   BRAF   in a series of 48 patients by Benvenuti et al. (  33  ), 
who also found that transfection of mutated   KRAS   (G12V) into 
wild-type DiFi colorectal cancer cells confers resistance to cetux-
imab.   KRAS   mutations have since emerged as a major predictor of 
resistance to panitumumab or cetuximab in the clinical setting. 
Studies (  27  ,  34  ,  36  ,  55    –    60  ) of patients receiving first and subsequent 
lines of treatment have found that those with tumors carrying 
  KRAS   mutations do not respond to EGFR-targeted monoclonal 
antibodies or experience any survival benefit from such treatment. 
Indeed, the progression-free interval in patients with tumors car-
rying mutant   KRAS   generally appears to be approximately half that 
of those patients whose tumors carry wild-type   KRAS   (  Table 2  ).         
  The pivotal randomized phase III study of panitumumab 
monotherapy in the relapsed or refractory setting (  13  ) was the ﬁ  rst 
large study (n = 463 patients) to conﬁ  rm the negative predictive 
value of   KRAS   mutations (  27  ). Biomarker analysis of primary 
tumor tissue was planned in the protocol and   KRAS   analysis was 
performed in a blinded manner at a central laboratory by use of a 
  KRAS   testing kit (DxS Ltd, Manchester, UK) (  27  ). Among the 463 
patients enrolled in this study, 427 (92%) were included in the 
  KRAS   analysis. Of these 427, 184 (43%) were found to have 
tumors harboring mutant   KRAS  : 84 (40%) of the 208 patients 
randomly assigned to panitumumab plus best supportive care and 
100 (46%) of the 219 patients assigned to best supportive care 
alone. Among the 208 patients assigned to panitumumab, 21 
(17%) of the 124 patients in the wild-type   KRAS   subgroup 
achieved objective response, whereas none of the 84 patients in the 
mutant   KRAS   subgroup responded to this treatment. Median 
progression-free interval among those treated with panitumumab 
was 12.3 weeks among those in the wild-type   KRAS   subgroup and 
7.4 weeks among those in the mutant   KRAS   subgroup. The hazard 
ratio (HR) for disease progression or death (panitumumab vs con-
trol group) was 0.45 (95% conﬁ  dence interval [CI] = 0.34 to 0.59) 
for panitumumab in the wild-type   KRAS   subgroup, but there was 
no beneﬁ  t of panitumumab in the mutant   KRAS   subgroup (HR = 
0.99, 95% CI = 0.73 to 1.36) (  Figure 2  ). A sensitivity analysis that 
adjusted for potential bias from unscheduled assessment found 
similar results. A total of 168 (77%) of the 219   KRAS  -evaluable 
patients initially assigned to the control group crossed over to 
receive panitumumab after disease progression, at a median time of 
7.1 weeks; this crossover confounded analysis of overall survival. 
Among these 168 patients, 20 (22%) of the 91 in the wild-type 
  KRAS   subgroup, compared with none in the mutant   KRAS   sub-
group, responded to panitumumab treatment; it is important to 
note that these results were based on local review, whereas tumor 
response in the main study was based on central review (  27  ).         
    KRAS   data from three large randomized phase II  –  III cetuximab 
studies have recently been published, including the ﬁ  rst-line 
OPUS (ie, Oxaliplatin and Cetuximab in First-Line Treatment of 
metastatic colorectal cancer) (  28  ) and CRYSTAL (ie, Cetuximab 
Combined With Irinotecan in First-Line Therapy for Metastatic 
Colorectal Cancer) (  29  ) studies and the NCIC-CTG (ie, National 
Cancer Institute of Canada-Clinical Trials Group) monotherapy 
study conducted in relapsed or refractory patients or those with 
contraindications to chemotherapy (  55  ). Data from 394 (69%) of 
the 572   KRAS  -evaluable patients participating in the phase III 
NCIC  –  CTG trial conﬁ  rmed that patients with tumors carrying 
  KRAS   mutations do not beneﬁ   t from cetuximab monotherapy. 
Both progression-free and overall survival were similar for the 
cetuximab and control groups in those patients with tumors carry-
ing   KRAS   mutations (progression-free interval = 1.8 vs 1.8      
months [HR = 0.99, 95% CI = 0.73 to 1.35,   P   = .96]; overall 
survival = 4.6 vs 4.5 months [HR = 0.98, 95% CI = 0.70 to 1.37,   P   = 
.89]). However, in the subgroup whose tumors carried wild-type 
  KRAS  , cetuximab treatment was associated with statistically 
signiﬁ  cantly (  P   < .001) longer survival than control treatment 
(progression-free interval = 3.7 vs 1.9 months [HR = 0.40, 95% 
CI = 0.30 to 0.54]; overall survival = 9.5 vs 4.8 months [HR = 0.55, 
95% CI = 0.41 to 0.74,   P   < .001      ]) (  55  ). It should be noted that 
unlike the pivotal panitumumab phase III study (  13  ), the design of 
this study did not allow patients from the control group who had 
disease progression to cross over to monoclonal antibody treat-
ment. Final retrospective data from the OPUS and CRYSTAL 
studies indicate that the addition of cetuximab to ﬁ  rst-line 
FOLFOX (folinic acid, ﬂ   uorouracil, and oxaliplatin) (  28  ) or 
FOLFIRI (folinic acid, ﬂ  uorouracil, and irinotecan) (  29  ) chemo-
therapy does not beneﬁ   t patients with tumors carrying   KRAS   
mutations, although those patients can beneﬁ  t from chemotherapy 
alone (  Table 2  ). Indeed, ﬁ  ndings of the OPUS study indicate that 
addition of EGFR-targeted treatment to chemotherapy may even 
be detrimental in such patients (  28  ) (  Table 2  ). 
  In the PACCE (ie, Panitumumab Advanced Colorectal Cancer 
Evaluation) study (  16  ), adding panitumumab to bevacizumab and 
chemotherapy was associated with shortening of the progression-
free interval among patients with tumors carrying wild-type   KRAS   
(11.5 months in the chemotherapy  –  bevacizumab arm vs 9.8 
months in the panitumumab-chemotherapy  –  bevacizumab arm). In 
the CAIRO (ie, Capecitabine, Irinotecan, and Oxaliplatin trial)  –  2 
study (  17  ), addition of cetuximab to capecitabine, oxaliplatin, and 
bevacizumab as ﬁ   rst-line treatment in patients with metastatic 
colorectal cancer had no effect on progression-free interval among 
those with tumors carrying wild-type   KRAS   (10.6 months in the 
chemotherapy  –  bevacizumab arm vs 10.5 months in the combined 
cetuximab arm). However, this combination had a marked detri-
mental effect among patients with tumors carrying mutated   KRAS   
(12.5 vs 8.1 months) (  17  ). 
  The proportion of patients bearing wild-type   KRAS   tumors 
who fail to achieve either objective response or disease stabilization 
with panitumumab or cetuximab varies considerably between 
studies (  Table 2  ). Among a total of 124 patients with such tumors 
who were treated with panitumumab in the pivotal phase III study, 
45 (36%) had a best response of progressive disease (  61  ). These 
patients had a median progression-free interval of 7.3 weeks, as 
shown by a post hoc subanalysis (  Figure 3  ). However, among 
patients with stable disease or a partial response, median progression-
free interval was 23.9 and 27.0 weeks, respectively (  61  ).         
  It is interesting to note that in other solid tumor settings, 
EGFR inhibitors (tyrosine kinase inhibitors or cetuximab) have 
shown minimal activity in patients with pancreatic cancer (  62  ,  63  ), 
which is associated with a very high prevalence of   KRAS   mutations 
(approximately 90%) (  64  ), and in patients with lung cancer whose 
tumors carry   KRAS   mutations (  65    –    67  ).   1312   Review | JNCI  Vol. 101, Issue 19  |  October 7, 2009
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    BRAF Mutations.             Recently published retrospective analysis (  40  ) 
of 113 tumors from patients who received panitumumab or cetux-
imab in second or subsequent lines of treatment showed that those 
with tumors that carried   BRAF   V600E mutations (n = 11, 10%) did 
not respond to EGFR inhibition and had statistically significantly 
shorter progression-free interval (  P   = .001) and overall survival (  P   < 
.001) than patients whose tumors carried wild-type   BRAF   (n = 34). 
A similar pattern was observed in an analysis of 231 tumors from 
patients treated with first-line cetuximab plus capecitabine, oxalipa-
tin      , and bevacizumab in the CAIRO-2 study (  41  ). The median 
progression-free interval and overall survival were 6.6 and 15.2 
months for patients with tumors carrying mutant   BRAF   (n = 28), vs 
10.4 (  P   = .01) and 21.5 (  P   = .001) months in those with tumors car-
rying wild-type   BRAF   (n = 231). However, the response rate did not 
differ between these two patient subgroups (39% vs 48%;   P   = .04). 
  Di Nicolantonio et al. (  40  ) also demonstrated that introduc-
tion of the   BRAF         V600E allele could confer resistance to either 
cetuximab or panitumumab in wild-type   BRAF   colorectal cancer 
cells. Furthermore, they showed that the multikinase inhibitor 
sorafenib may restore sensitivity to EGFR inhibitors in   BRAF  -
mutated colorectal cancer cell lines. Consequently, combined 
sorafenib and cetuximab therapy is undergoing clinical evaluation 
in metastatic colorectal cancer in a National Cancer Institute  –
  sponsored trial (NCT00343772;     http  ://  clinicaltrials  .  gov  /  ct2  /  show  / 
NCT00343772    ). Evaluation of EGFR-targeted antibodies in 
combination with other novel and more selective   BRAF   inhibi-
tors, such as PLX-4032 and XL-281, is also warranted.   
    PTEN and PI3K.             Loss of expression of the tumor suppressor 
PTEN protein, which regulates the PI3K  –  Akt signaling path-
way, has been reported to confer tumor resistance to EGFR 
tyrosine kinase inhibitors in vitro (  68  ) and has been linked to 
erlotinib resistance in patients with glioblastoma (  69  ) and to 
trastuzumab resistance in patients with breast cancer (  70  ). In 
vitro studies in various colon cancer cell lines have found that 
activating   PIK3CA   mutations or loss of PTEN expression 
        Figure 2    .        Progression-free interval and   KRAS   
mutation status of tumor in patients with meta-
static colorectal cancer who were randomly 
assigned to treatment with best supportive care 
(BSC) alone or panitumumab (Panit) plus BSC in a 
phase III study (  27  ).   A  ) Tumors with mutant   KRAS   
status.   B  ) Tumors with wild-type   KRAS   status (  27  ) 
(with permission from the American Society of 
Clinical Oncology). CI = conﬁ  dence interval; HR = 
hazard ratio.         jnci.oxfordjournals.org    JNCI | Review 1315
appeared to confer resistance to cetuximab. Cell lines that had 
mutations in   PIK3CA  , or were PTEN null, and also had muta-
tions in   RAS   or   BRAF   exhibited the greatest resistance to cetux-
imab (  71  ). Similarly, in the clinical setting, deregulation of either 
PIK3CA       or   PTEN   gene (via mutation or loss of expression;   P   = .02) 
(  38  ) or PTEN protein expression loss alone (  P   < .001) (  58  ) statis-
tically significantly impaired response to cetuximab-based treat-
ment in colorectal cancer patients. Frattini et al. (  58  ) reported 
that none of 11 patients with tumor PTEN loss responded to 
cetuximab-based treatment, whereas 10 (63%) of 16 patients 
with intact PTEN protein expression were partial responders. 
Perrone et al. (  38  ) also noted that none of three patients with 
  PTEN   mutation responded to treatment with cetuximab and 
irinotecan. In a total of 92 patients with metastatic colorectal 
cancer who were included in three biomarker analyses ( 26  ,  34  ,  38  ), 
nine (10%) had tumors bearing   PIK3CA   mutations and only one 
responded to EGFR-targeted treatment. In a larger patient 
series (n = 110), Sartore-Bianchi et al.     (  72  ) found that   PIK3CA   
mutations and PTEN loss in colorectal tumors were statistically 
significantly associated with lack of response to panitumumab 
(zero of 15 patients,   P   = .038) or cetuximab (one of 32 patients, 
  P   = .001) treatment. In the same study,   PIK3CA   mutations and/
or loss of PTEN expression were negatively associated with 
progression-free interval, and loss of PTEN expression was also 
linked with poorer overall survival (  P   = .005). These investiga-
tors suggested that combining mutation analysis for   KRAS   and 
  PIK3CA   (loss of   PTEN   and/or   PIK3CA   mutation) could identify 
up to 70% of patients with metastatic colorectal cancer who are 
unlikely to respond to treatment with an EGFR-targeted 
monoclonal antibody (  72  ). Contradictory evidence was recently 
reported by Prenen et al. (  73  ) who found no strong rationale for 
using   PIK3CA   mutations as a single marker for sensitivity to 
cetuximab in chemotherapy-refractory metastatic colorectal 
cancer. Razis et al. (  74  ) reported that normal PTEN protein 
expression was associated with a higher response rate and longer 
time to progression in patients treated with cetuximab-based 
therapy, despite a 50% response rate observed in patients who 
had lost PTEN protein expression (  74  ). Because this study 
included patients treated with first-line cetuximab and chemo-
therapy, these findings are difficult to interpret. Further inves-
tigation and prospective data from large randomized clinical 
trials are required to confirm these findings before they can be 
integrated into clinical practice. 
  Because tumors with oncogenic   PIK3CA   mutations are likely to 
be driven by PI3K as the primary source of growth, proliferation, 
and survival signaling (  Figure 1  ), the use of selective PI3K inhibi-
tors is being tested in ongoing trials. Indeed, several PI3K inhibi-
tors are progressing from preclinical development to phase I 
clinical studies. This family of compounds includes XL147, GDC-
0941, BGT226, and the pan-PI3K  –  mammalian target of rapamycin 
(mTOR) inhibitors XL765 and NVP-BEZ235 (  75  ). The combina-
tion of cetuximab and the mTOR inhibitor everolimus has been 
shown to be effective in restoring growth inhibition in cetuximab-
resistant colorectal cancer cells (  76  ). It remains to be evaluated in 
clinical trials whether concomitant inhibition of the EGFR and 
PIK3CA pathways (  Figure 1  ) will convey clinical beneﬁ  t. 
  In addition, in colorectal cancer, the incidence of   PIK3CA   and 
  BRAF   mutations (but not mutations of   KRAS   or   TP53  ) displays a 
gender bias with a higher frequency occurring in women (  32  ,  77  ). 
Thus, it could be hypothesized that female patients with metastatic 
colorectal cancer might be less likely to beneﬁ  t from treatment 
with EGFR-targeted monoclonal antibodies. However, available 
clinical data do not support this hypothesis (  17  ,  27  ,  29  ).     
    EGFR as a Target 
  Many technical reasons have been advocated for the lack of asso-
ciation between EGFR detection by immunohistochemistry and 
response to EGFR-targeted treatment, as discussed by Shia et al. 
(  78  ). These reasons include disparity between the form or epitope 
of EGFR detected by immunohistochemistry and that targeted by 
        Figure 3    .        Progression-free interval by 
response to panitumumab in a subgroup of 
patients with metastatic colorectal cancer 
whose tumors carry wild-type   KRAS.   Data 
are from a phase III study (  27  ,  61  ).         1316   Review | JNCI  Vol. 101, Issue 19  |  October 7, 2009
anti-EGFR monoclonal antibodies, as well as issues related to 
processing and handling of tumor tissue samples, such as pro-
longed storage. Immunohistochemistry is also a semiquantitative 
method that lacks a standardized scoring system and is subject to 
interobserver variation. Moreover, differences between primary 
colorectal tumors and their metastases with regard to EGFR 
expression have been reported (  79  ), indicating that reliance on 
such biomarkers in the primary tumor to predict treatment 
response of metastatic growths may be inappropriate. 
    EGFR Affinity and Phosphorylation.             Using a specific ligand-
binding assay, Francoual et al. (  80  ) found that many tumors con-
tain both low- and high-affinity EGFRs: 64 (78%) of 82 tumor 
specimens contained only high-affinity binding sites (median dis-
sociation constant = 0.75 nM) and 18 (22%) had both low- and 
high-affinity sites. Because immunohistochemistry-based methods 
cannot distinguish between low- and high-affinity EGFR, these 
findings may provide further explanation for the lack of correlation 
between EGFR immunostaining and clinical response to EGFR-
targeted treatment. 
  EGFR phosphorylation status may reﬂ  ect the level of receptor 
utilization by the tumor. This parameter (as determined by immu-
nohistochemistry) was associated with clinical response in patients 
treated with cetuximab-based therapy. Patients with an activated 
or phosphorylated EGFR score, as indicated by an immunohis-
tochemistry-based visual score of 7 or greater, were almost twice as 
likely to have disease control (objective response or stable disease) 
than those with a score of less than 7 (100% vs 54%;   P   = .05) (  81  ).   
    EGFR Gene Status.             Activating mutations, including in-frame 
deletions and amino acid substitutions in exons 18, 19, and 21 in 
the   EGFR   catalytic domain, play an important role in determining 
responsiveness to tyrosine kinase inhibitors in the lung cancer set-
ting (  82  ,  83  ). Such mutations are rare (  26  ,  84  ) or absent (  57  ,  85  ) in 
colorectal cancer tumors. Moroni et al. (  26  ) detected one mutation 
(3.2%) among 31 patients with metastatic colorectal cancer, occur-
ring in a patient who achieved stable disease for 24 weeks with 
cetuximab and chemotherapy treatment. This missense heterozy-
gous mutation in exon 21 (Gly857Arg) affected a residue located 
within the activation loop of the   EGFR   catalytic domain and was 
one amino acid away from the Leu858Arg-activating mutation that 
has been identified in patients with lung cancer who respond to 
gefitinib or erlotinib (  86  ). At disease progression, the patient 
whose tumor had this mutation was treated with gefitinib; this 
molecular alteration in EGFR was not associated with clinical 
response because the disease progressed after 4 weeks of treatment. 
Notably, a specific polymorphism of   EGFR   affecting exon 13 at 
residue 521 Arg/Arg (previously identified as residue 497, 
rs11543848) has been linked with improved overall survival in 
women with metastatic colorectal cancer (vs Lys/Lys and/or Lys/
Arg variants), although the reverse pattern was observed in men 
with this disease (  87  ). This same polymorphism has been linked to 
cetuximab response in other studies (  88    –    90  ). Conflicting evidence 
also exists for a polymorphism affecting the ligand of EGFR, EGF, 
at position 61 (rs4444903) (  89  ,  91  ,  92  ). 
  A small proportion of colorectal tumors overexpress EGFR via 
ampliﬁ  cation of the gene, which can be detected by ﬂ  uorescence in 
situ hybridization (FISH) (  93  ) or chromogenic in situ hybridization 
(  78  ). Although the intensity of protein expression was associated 
with the likelihood of gene ampliﬁ  cation, immunohistochemistry 
had a low speciﬁ  city (17% in primary tumors and 23% in meta-
static tumors) for predicting gene ampliﬁ  cation (  78  ). 
  When   EGFR   gene copy number was evaluated by polymerase 
chain reaction, no association was found between this parameter 
and clinical outcome of panitumumab- or cetuximab-based treat-
ment (  26  ,  57  ,  85  ), probably because of tumor DNA dilution by 
DNA from normal cells during DNA extraction. However,   EGFR   
gene copy number as analyzed by FISH or chromogenic in situ 
hybridization appears to be a promising biomarker of response to 
such treatment (  Table 3  ), and present technical limitations are 
being addressed in pathology studies (  97  ). Methods of tissue pro-
cessing and   EGFR   scoring systems differed between studies. 
Moreover, FISH pattern for   EGFR   expression is often nonhomo-
geneous in colorectal cancer tumors, with variable ratios of disomy 
vs polysomy or ampliﬁ  cation being observed (  93  ,  94  ). Increased 
gene copy number was found in at least 30% of patients when a 
threshold value of approximately three   EGFR   copies per nucleus 
was used, as determined by FISH, compared with only 10% of 
patients when a threshold of six or more   EGFR   copies per nucleus 
was used, as determined by chromogenic in situ hybridization 
(  Table 3  ). Statistically signiﬁ  cant concordance between primary 
colorectal tumors and their metastases with regard to   EGFR   gene 
copy number has been found, as identiﬁ  ed by FISH (  95  ,  96  ).         
  Available data suggest that patients with less than three   EGFR   
gene copies per nucleus have a relatively low likelihood of respond-
ing to EGFR-targeted monoclonal antibody treatment (  34  ,  56  ,  94    –
    96  ). In a retrospective analysis of a subgroup of patients participating 
in the pivotal phase III trial of panitumumab monotherapy (  94  ), 
the mean   EGFR   gene copy number per nucleus and the percentage 
of tumor cells with chromosome 7 polysomy (three or more   EGFR   
signals per nucleus) were analyzed by FISH and the association 
between these parameters and clinical outcome was assessed. None 
of the patients with a mean of <2.47   EGFR   gene copies per nucleus 
or fewer than 43% of tumor cells with chromosome 7 polysomy, 
respectively, achieved objective response compared with six (30%) 
of the 20 patients (  P   = .001) and six (32%) of the 19 patients (  P   = 
.001) who had values above these thresholds. A mean   EGFR   gene 
copy number threshold of less than 2.5 copies per nucleus or fewer 
than 40% of tumor cells with chromosome 7 polysomy discrimi-
nated patients with shorter progression-free (  P   = .039 and   P   = .029, 
respectively) and overall survival (  P   = .015 and   P   = .014, respec-
tively).   EGFR   gene copy number and chromosome 7 polysomy 
status did not draw a parallel with progression-free interval in 
patients receiving only supportive care in this study, suggesting 
that this parameter is not prognostic in metastatic colorectal can-
cer (  94  ). These data contrast with earlier ﬁ  ndings that were based 
on quantitative polymerase chain reaction analysis (  85  ) showing 
that   EGFR   gene copy number, as assessed by this method, related 
to neither clinical response nor progression-free interval. 
Homogeneous (ie, 100%) chromosome 7 disomy was the most 
common pattern found in 58 colorectal tumors with nonincreased 
gene copy number (n = 26; 45%) (  94  ). Chromosome 7 disomy is 
easier to detect than an increase in   EGFR   gene copy number and, 
therefore, might enable a more reproducible FISH assay. However, jnci.oxfordjournals.org    JNCI | Review 1317
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methods need to be further standardized for better reproducibility 
and optimum sensitivity (  96  ,  97  ). 
  In comparison with patients with normal   EGFR   gene copy num-
ber, patients with an increased   EGFR   gene copy number exhibit 
higher response rates to EGFR-targeted monoclonal antibodies, 
with a longer progression-free interval or time to progression 
(  34  ,  58  ,  94    –    96  ) (  Table 3  ). Two studies found that six (30%) of 
20 patients and 14 (33%) of 43 patients with increased   EGFR   gene 
copy number had an objective response to panitumumab (  94  ) or 
cetuximab with or without chemotherapy (  95  ). Such response rates 
compare favorably with historical response rates reported for popu-
lations selected by EGFR immunostaining alone. Higher response 
rates were seen in other studies (  Table 3  ). For instance, Moroni et al. 
(  26  ) found an 89% response rate in a subgroup of nine patients with 
colorectal cancer whose tumors had an increased   EGFR   gene copy 
number, but these investigators included a relatively high propor-
tion of responders (nine of 29 patients; 31%) in their analysis. In 
vitro studies by these investigators also showed that the proliferation 
of various colorectal cancer cell lines with ampliﬁ  ed EGFR was 
completely inhibited by cetuximab at concentrations that did not 
affect proliferation of cells with unampliﬁ  ed EGFR (  26  ). Logistic 
regression analysis indicated that the odds ratio for response to pani-
tumumab was 5.62 (95% CI = 1.51 to 21.0) for increased vs normal 
mean   EGFR   gene copy number (  94  ).   
    Overexpression of Other EGFR Ligands.             Elevated gene expres-
sion of alternative EGFR ligands, such as epiregulin and amphi-
regulin, may promote tumor growth and survival via an autocrine 
loop (  59  ,  98  ). Expression of high levels of mRNA for either epi-
regulin or amphiregulin has been associated with sensitivity to 
cetuximab monotherapy (  59  ,  98  ). Comparison of clinical outcomes 
for patients with high and low levels of these ligands showed a 
statistically significantly improved disease control rate (  P   < .001) 
and longer progression-free interval among patients with high 
expression of epiregulin (median = 103.5 vs 57 days,   P   < .001; 
HR = 0.47 [95% CI = 0.24 to 0.64]) or amphiregulin (median = 
115.5 vs 57 days,   P   < .001; HR = 0.44 [95% CI = 0.21 to 0.57]) (  59  ). 
The exclusive use of either   KRAS   status or amphiregulin or epi-
regulin gene expression profiles (  59  ) does not result in the selec-
tion of identical patient populations who are likely to benefit from 
treatment with cetuximab: Among patients with wild-type   KRAS  , 
patients whose tumors expressed high levels of amphiregulin or 
epiregulin were likely to experience disease control, whereas 
patients whose tumors expressed low levels of these genes were 
not, thus providing important complementary information to 
  KRAS   status (  99  ). Increased gene copy number of HER2       (the pre-
ferred heterodimer of EGFR) was linked to a statistically signifi-
cantly shorter overall survival (  P   = .03), with a trend toward a 
shorter time to progression (  P   = .09), in 85 patients receiving 
cetuximab with or without chemotherapy (  100  ).     
    Other Potential Biomarkers 
  Markers of angiogenesis and cell cycle regulation appear to be 
promising areas for further research. Angiogenesis is a prerequisite 
for growth and progression of tumors (  101  ,  102  ). Although driven 
by separate mechanisms, EGFR and the key angiogenic factor 
VEGF-1 share common downstream pathways ( Figure 1 ). Findings 
of preclinical studies (conducted in human tumor cell lines xeno-
grafted into murine models that evaluated the combined pharma-
cological targeting of EGFR-dependent and VEGF-dependent 
pathways) indicate direct or indirect angiogenic effects of EGFR 
signaling (  103    –    106  ). Furthermore, expression of VEGF-1 or its 
receptor has been linked to resistance to EGFR-targeted agents in 
various cancer cell lines (  107  ) and in patients with metastatic col-
orectal cancer (  108  ). Markers that have been positively linked to 
outcome in patients with metastatic colorectal cancer who were 
treated with EGFR-targeted monoclonal antibodies include 
expression or gene polymorphisms of cyclooxygenase-2 (  108  ,  109  ), 
interleukin-8 (  108  ,  109  ), and the cell cycle regulator cyclin D1 
(  93  ,  108  ,  109  ). For instance, Vallböhmer et al. (  108  ) concluded that 
a combination of low gene expression levels of cyclooxygenase-2, 
EGFR, and interleukin-8 was statistically significantly related to 
the overall survival of patients who were treated with cetuximab 
monotherapy (13.5 vs 2.3 months in those with high gene expres-
sion levels of these three genes;   P   = .028). Feedback mechanisms 
and complex cellular circuits further link expression of VEGF, 
interleukin-8, and cyclooxygenase-2 to the oncogenic activation of 
  KRAS   and   BRAF   genes. For example, expression of cyclooxyge-
nase-2, an upstream regulator of EGFR activity, is driven via the 
EGFR cascade (  Figure 1  ), and in particular oncogenic   KRAS   has 
been shown to induce cyclooxygenase-2 expression (  110  ,  111  ). In 
addition, increased expression of cyclooxygenase-2 may result in 
increased production of prostaglandin E2, which in turn can trans-
activate EGFR (  112  ). Expression of the transcription factor nuclear 
factor     B has also been linked with resistance to cetuximab (  113  ). 
  Polymorphisms in fragment c gamma receptors, surface recep-
tors for immunoglobulin G located on immune effector cells (such 
as natural killer lymphocytes and macrophages), are also of interest 
as potential markers of response to EGFR-targeted monoclonal 
antibodies, although data are conﬂ  icting at present (  109  ,  114    –    116  ). 
Fragment c gamma receptors are thought to play a role in antibody-
dependent cell-mediated cytotoxicity, which has been postulated as 
an additional mechanism of action for the IgG1 type of monoclonal 
antibodies, such as cetuximab, rituximab, and trastuzumab (  117  ). 
Although it was initially believed that panitumumab, as an IgG2 
monoclonal antibody, would not elicit antibody-dependent cell-
mediated cytotoxicity, this phenomenon has recently been demon-
strated in squamous cell head and neck carcinomas in vitro at 
concentrations that are analogous to therapeutic doses (  117  ). 
  Molecular brakes that protect against inappropriate oncogene 
activation (such as   TP53        ) may also be candidate biomarkers of 
sensitivity to anti-EGFR therapy, given that their inactivation may 
be required for tumor progression. Indeed, Oden-Gangloff et al. 
(  118  ) suggest that   TP53   mutations may be predictive of increased 
likelihood of response to cetuximab treatment, particularly in 
patients with wild-type   KRAS   status (  118  ).     
    Early Response Evaluation 
  The characteristic “acneiform” skin rash observed in most patients 
who are treated with EGFR inhibitors has been studied as a poten-
tial marker of efficacy. This adverse effect is usually apparent after 
approximately 1 week of treatment and reaches maximum severity 
after 2  –  3 weeks. As with the tyrosine kinase inhibitor erlotinib jnci.oxfordjournals.org    JNCI | Review 1319
in patients with lung cancer (  24  ,  119  ), skin toxicity has been con-
sistently linked with higher response rates and longer survival 
among patients with metastatic colorectal cancer who have 
been treated with panitumumab (  13  ,  120  ) or cetuximab (  7  ,  11  ,  12  ), 
whereas patients without rash appear to have a poor outcome. 
  Figure 4   illustrates the relationship between survival and worst 
grade of rash among patients treated with panitumumab (  13  ) or 
cetuximab (  12  ) monotherapy in two phase III studies. A landmark 
analysis (including only patients who were progression free for 
  ≥  28 days to allow time for onset) of progression-free interval data 
from the panitumumab study (n = 231) showed a statistically sig-
nificant benefit for patients with grade 2  –  4 skin toxicity compared 
with those with grade 1 skin toxicity (HR = 0.62, 95% CI = 0.44 
to 0.88) (  13  ).         
  Rash might indicate receptor saturation, and “dose-to-rash” 
strategies are being studied with the aim of optimizing response to 
EGFR-targeted treatment. Preliminary data from the phase I  –  II 
      Evaluation of Various Erbitux Regimens by means of Skin and 
Tumour biopsies (ie, EVEREST) study suggest that among patients 
receiving cetuximab-based treatment, cetuximab dose escalation to 
500 mg/m  2   per week may improve response rates in those with no or 
slight skin reactions (  121  ), but the difference was not statistically 
signiﬁ   cant and results require conﬁ   rmation in a larger study. 
Subsequent analysis of results by   KRAS   status showed that cetux-
imab dose escalation did not increase response in patients with 
tumors carrying a mutant   KRAS   gene. However, among those with 
tumors carrying wild-type   KRAS  , this strategy improved the 
response rate from four (21%) of 19 patients to 13 (46%) of 28 
patients (  122  ). It is important to note that the panitumumab regimen 
of 6 mg/kg every 2 weeks, which is approved for treatment of meta-
static colorectal cancer, achieves similar drug exposure to a regimen 
of 2.5 mg/kg per week, which was studied in early phase trials and 
was found to be associated with a 100% incidence of rash (  123  ). 
  There are several limitations to the use of rash as an early physi-
cal marker of efﬁ  cacy. As highlighted by De Roock et al. (  57  ), there 
are no criteria for toxic effects involving skin that are speciﬁ  cally 
tailored to the activity of EGFR-targeted treatment. Rash often 
occurs in patients without apparent beneﬁ  t from anti-EGFR treat-
ment, and conversely, clinical beneﬁ  t has also been seen in patients 
without rash (  124  ). Because EGFR is expressed in the skin, skin 
rash may indicate local receptor saturation, but other factors, such 
as their immune status, might alter an individual  ’  s susceptibility to 
rash. An association has been observed between tumor and normal 
tissue with regard to high-afﬁ  nity EGFR. This ﬁ  nding might pro-
vide an explanation for the link observed between skin toxicity and 
clinical outcome of patients treated with EGFR-targeted treat-
ment (  81  ). Moreover, the relationship between rash and clinical 
beneﬁ  t is inconsistent for the tyrosine kinase inhibitor geﬁ  tinib 
(  124  ) and, intriguingly, rash is not observed in patients treated 
with the humanized anti-EGFR monoclonal antibody nimotu-
zumab (  125  ,  126  ), although it should be noted that efﬁ  cacy data for 
this drug are currently limited. 
  Anti-EGFR monoclonal antibody treatment may compromise 
renal magnesium retention capacity, leading to hypomagnesemia 
in some patients with colorectal cancer (  127  ). Vincenzi et al. (  128  ) 
recently suggested that reduction in serum magnesium levels 
might potentially provide an early marker of efﬁ  cacy of combined 
treatment with cetuximab and irinotecan. It has also been sug-
gested that treatment with cetuximab may induce a sudden and 
lasting modulation of circulating VEGF levels (  129  ), although 
the association between this ﬁ  nding and clinical efﬁ  cacy was not 
reported.   
    Discussion and Future Perspectives 
  Although the link between clinical benefit and overexpression of 
the molecular target is clear for trastuzumab and imatinib and their 
respective targets (HER2 and the BCR-ABL tyrosine kinase), 
experience has shown that positive expression of EGFR as shown 
by immunostaining is not predictive of response to EGFR inhibi-
tors. It is now clear that tumor growth can be driven by constitutive 
activation of signaling pathways downstream of the EGFR, such as 
the RAS  –  MAPK  –  PI3K pathway. Oncogenic activation of compo-
nents in these pathways can bypass the EGFR-driven signaling 
cascade and impair the clinical efficacy of anti-EGFR monoclonal 
antibodies. Such activation can occur via mutations in oncogenes 
such as   KRAS   or   BRAF   on one side of the EGFR-mediated path-
way or by   PIK3CA   mutation or loss of tumor suppressor genes 
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      Figure 4    .        Probability of survival by worst grade of skin toxicity in 
patients with metastatic colorectal cancer who were treated with EGFR-
targeted monoclonal antibodies in two randomized phase III studies.   A  ) 
Patients treated with panitumumab. Data are from a landmark analysis 
that was limited to patients with progression-free interval of at least 28 
days (  13  ) (with permission from the American Society of Clinical 
Oncology.   B  ) Patients treated with cetuximab (  12  ). Reproduced with 
permission from the   New England Journal of Medicine  . Copyright 2007 
Massachusetts Medical Society. All rights reserved. CI = conﬁ  dence 
interval; HR = hazard ratio.       1320   Review | JNCI  Vol. 101, Issue 19  |  October 7, 2009
such as   PTEN   on the opposite side of the cascade (  72  ) (  Figure 1  ). 
These findings may provide some explanation for the rather 
modest objective response rates that have been achieved with clini-
cal trials of EGFR inhibitors to date, as well as the disparities 
observed between clinical and preclinical findings. It should also 
be noted that preclinical models are based on particular tumor 
subtypes that may not be representative of most tumors encoun-
tered in clinical practice. 
    Table 4   summarizes potential biomarkers that may be related to 
primary response to the anti-EGFR monoclonal antibodies, pani-
tumumab and cetuximab. Overall, presently available data reviewed 
in this article provide convincing evidence that activating muta-
tions of   KRAS  , which are present in a substantial proportion of 
patients with metastatic colorectal cancer, predict lack of response 
to anti-EGFR monoclonal antibody treatment ( 27    –    29  ,  33  ,  34  ,  55  ,  60  ). 
This ﬁ  nding is consistent with observations from use of EGFR 
tyrosine kinase inhibitors in the treatment of non  –  small cell lung 
cancer, although   KRAS   mutations are less common in lung tumors 
(  66  ,  67  ).         
    KRAS   testing is now being integrated into clinical practice. The 
European Medicines Agency’s conditional approval of panitumumab 
monotherapy in the setting of chemorefractory metastatic colorectal 
cancer speciﬁ  ed wild-type   KRAS   as a selection marker (134). 
Current data indicate that objective response rates of up to 22% can 
be expected in such patients (Table 2). It should be noted that clini-
cal beneﬁ  t is not conﬁ  ned to objective responders because delaying 
disease progression can improve clinical symptoms and the patient’s 
quality of life (135). Wild-type   KRAS   was more recently identiﬁ  ed 
as a selection marker for cetuximab monotherapy or combination 
therapy (136). The European Medicines Agency (20, 130), the US 
Food and Drug Administration (137), and the American Society of 
Oncology (131) now recommend determining tumor   KRAS   status 
before initiating treatment with an anti-EGFR monoclonal anti-
body and restricting such treatment to patients with tumors bearing 
wild-type   KRAS  . 
  Because of the complexity of the EGFR signaling system, it is 
likely that predictive algorithms will be developed for metastatic 
colorectal cancer that incorporate several molecular biomarkers. 
For instance, combining analysis of   KRAS   status with determina-
tion of   BRAF   and   PIK3CA   status and PTEN expression may iden-
tify additional patients with metastatic colorectal cancer who are 
unlikely to respond to treatment with an EGFR-targeted mono-
clonal antibody (  133  ). However, these additional markers (  Table 4  ) 
require further validation before they can be incorporated into 
clinical practice. 
  Tumors with an increased   EGFR   gene copy number as assessed 
by FISH or chromogenic in situ hybridization may be dependent 
on the EGFR pathway for their survival and growth. There is 
evidence that normal diploid   EGFR   gene copy number may predict 
tumor resistance to EGFR-targeted treatment (  Table 3  ). Again, 
further research is required to validate this biomarker in larger 
patient series (  97  ). 
  There are clearly a number of technical issues to be overcome, 
particularly standardization of analytical methods and scoring sys-
tems. Lack of standardization may well explain some of the discordant 
results that have been reported. Certainly, some biomarkers may not 
prove suitable for translation into clinical practice. However, DNA 
sequencing of formalin-ﬁ  xed parafﬁ  n-embedded tumor samples is a 
relatively straightforward method for identifying   KRAS   mutations. 
Because   KRAS   mutation is an early event in colorectal cancer tumori-
genesis (  42  ,  43  ), archived primary tumor tissue can be used to identify 
patients who are unlikely to respond to EGFR-targeted monoclonal 
antibodies, even after multiple lines of treatment. A   KRAS   testing kit 
from DxS Ltd can identify the following seven somatic mutations in 
  KRAS   codons 12 and 13: Gly12Ala, Gly12Arg, Gly12Asp, Gly12Ser, 
Gly12Cys, Gly12 Val, and Gly13Asp. The polymerase chain reac-
tion  –  based technique used is highly sensitive but does not detect less 
frequent changes that can be detected with direct sequencing (eg, 
Gly13Val, Gly13Ala, and Gly13Cys). Although direct sequencing has 
the capability to detect all changes at the nucleotide level, it is less 
  Table 4    .       Summary of potential predictive molecular biomarkers for response to the epidermal growth factor receptor (EGFR)  –  targeted 
monoclonal antibodies cetuximab and panitumumab in metastatic colorectal cancer  *     
    Relationship to response Biomarker First author (reference)   
    Predicts lack of response and now 
  incorporated into clinical practice    †   
  KRAS   mutation Amado (  27  ); Bokemeyer (  28  ); Van Cutsem 
 (  29  );   Table 2  , this article; (  20  ,  130  ,  131  ) 
  Very likely to predict lack of response Mutation or lack of expression of PTEN; mutation 
 of    BRAF   or   PIK3CA 
Frattini (  58  ); Perrone (  38  ); Benvenuti (  33  ); 
  Di Nicolantonio (  40  ); Sartore-Bianchi (  72  ); 
  Di Nicolantonio (  132  ) 
  May predict lack of response    ‡    Increased HER2 gene copy number Finocchiaro (  100  ) 
  May predict increased likelihood of response Increased   EGFR   gene copy number  §   Table 3  , this article 
  Increased EGFR phosphorylation    ‡   Personeni  (  81  ) 
  Overexpression of alternative EGFR ligands 
  (amphiregulin and/or epiregulin)    ‡   
Khambata-Ford (  59  ) 
  pAKt overexpression    ‡   Razis  (  133  ) 
  Other potential markers Markers of angiogenesis and cell cycle regulation; 
  transcription factors (VEGF, IL-8, COX-2, cyclin D, 
 NF    B)    ‡   
Vallböhmer (  108  ); Nagashima (  109  ); 
 Zhang  (  92  )   
    *     Data are based on analysis of tumor tissue from patients participating in clinical trials. COX-2 = cyclooxygenase-2; HER2 = human epidermal growth factor-2; 
IL-8 = interleukin-8; NF    B = Nuclear factor kappa B; pAkt = phosphorylated Akt; VEGF = vascular endothelial growth factor.   
      †       Based on data from a study that prospectively defined biomarker analysis and included a large number of patients (  13  ).   
      ‡       Limited preliminary data.   
    §     Data need to be confirmed in large patient datasets, preferably with prospective study design.     jnci.oxfordjournals.org    JNCI | Review 1321
sensitive and may occasionally miss mutations, especially if the frac-
tion of tumor vs normal cells is low (  57  ). Testing will be facilitated by 
gene panel microarray technology and gene panels that incorporate 
  KRAS   testing are being evaluated (  138  ). 
  Further work is also required to explore potential early markers 
of response (in patients already receiving EGFR-targeted treat-
ment) that can be incorporated into the design of future prospec-
tive clinical trials and guide therapeutic decisions regarding 
continuation of treatment in individual patients. Skin toxicity 
develops at an early stage in treatment with EGFR inhibitors and 
has been studied extensively as a potential early marker of response, 
although further work is required. 
  Virtually all responding tumors eventually “escape” from 
EGFR-targeted treatment (ie, develop acquired resistance). In the 
lung cancer setting, acquired resistance to erlotinib or geﬁ  tinib has 
been attributed to development of a secondary mutation within the 
  EGFR   catalytic domain (  139  ). Other potential escape mechanisms 
include activation of alternative signaling pathways contributing to 
proliferation and survival, such as those involving activation of 
HER2, HER3, mesenchymal –  epithelial transition factor (C-MET), 
insulin-like growth factor-I receptor      , MAPK, and Akt (  140  ). 
Consequently, identiﬁ  cation of the molecular basis of acquired 
resistance to anti-EGFR monoclonal antibodies in metastatic col-
orectal cancer should be a priority for future research. 
  In conclusion, the quest for predictive biomarkers of response to 
EGFR inhibitor therapy has resulted in a rapidly accumulating body 
of knowledge that has paved the way for more targeted use of these 
agents. More rational use of EGFR-targeted agents should provide 
beneﬁ   ts for patients and health-care providers alike by sparing 
patients unnecessary treatment and allowing better use of health-
care resources. Prospective biomarker-driven studies are now under 
way, but in the meantime, the identiﬁ  cation of wild-type   KRAS   
as a selection biomarker for panitumumab or cetuximab therapy 
represents an important step toward fulﬁ  lling the promise of 
individualized treatment for metastatic colorectal cancer.   
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